南新制药
(688189)
| 流通市值：24.56亿 | | | 总市值：24.56亿 |
| 流通股本：2.74亿 | | | 总股本：2.74亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 278,087,147.14 | 301,518,768.62 | 427,810,114.4 | 439,384,715.69 |
| 应收票据及应收账款 | 29,659,502.81 | 37,076,552.76 | 63,070,155.89 | 79,246,358.7 |
| 其中：应收票据 | 19,160 | 1,042,186.5 | 483,448 | 1,434,788 |
| 应收账款 | 29,640,342.81 | 36,034,366.26 | 62,586,707.89 | 77,811,570.7 |
| 应收款项融资 | 3,935,178.76 | 5,436,438.38 | 8,219,717.55 | 921,367.69 |
| 预付款项 | 4,157,966.21 | 3,067,834.26 | 8,360,652.99 | 7,633,287.85 |
| 其他应收款合计 | 1,879,724.81 | 1,020,811.38 | 2,053,045.02 | 2,659,791.01 |
| 其中:应收利息 | - | - | - | 770,250 |
| 存货 | 42,180,672.73 | 35,876,290.12 | 47,548,168.68 | 55,636,697.39 |
| 其他流动资产 | 15,734,285.75 | 15,830,554.65 | 16,852,837.1 | 16,943,090.76 |
| 流动资产合计 | 375,634,478.21 | 399,827,250.17 | 573,914,691.63 | 602,425,309.09 |
| 非流动资产: | | | | |
| 固定资产 | 140,792,647.06 | 145,179,838.01 | 149,879,516.84 | 154,894,165.41 |
| 在建工程 | 4,904,472.37 | 4,904,472.37 | 5,525,266.65 | 2,463,255.51 |
| 无形资产 | 86,481,666.6 | 88,871,795.8 | 130,894,665.77 | 134,974,019.3 |
| 开发支出 | 125,707,651.63 | 117,995,353.58 | 106,823,945.22 | 106,823,945.22 |
| 长期待摊费用 | 403,644.93 | 420,207.9 | 105,998.69 | 111,434.51 |
| 递延所得税资产 | 34,245,561 | 33,741,554.64 | 51,144,346.2 | 51,190,114.43 |
| 其他非流动资产 | 18,531,650 | 18,531,650 | 15,600,000 | 16,742,500 |
| 非流动资产合计 | 411,067,293.59 | 409,644,872.3 | 459,973,739.37 | 467,199,434.38 |
| 资产总计 | 786,701,771.8 | 809,472,122.47 | 1,033,888,431 | 1,069,624,743.47 |
| 流动负债: | | | | |
| 短期借款 | 10,000,000 | 10,030,478.89 | 148,199,491.66 | 148,166,825 |
| 应付票据及应付账款 | 29,344,280.27 | 27,232,736.15 | 16,754,249.4 | 15,756,452.79 |
| 应付账款 | 29,344,280.27 | 27,232,736.15 | 16,754,249.4 | 15,756,452.79 |
| 合同负债 | 4,166,366.92 | 1,957,254.52 | 2,201,713.49 | 2,638,563.1 |
| 应付职工薪酬 | 7,779,451.65 | 8,375,509.15 | 10,451,662.87 | 11,700,779.75 |
| 应交税费 | 1,355,573.03 | 1,455,514.61 | 1,450,079.21 | 1,602,635.16 |
| 其他应付款合计 | 27,014,217.16 | 33,830,074.41 | 40,350,677.36 | 41,754,834.32 |
| 其他流动负债 | 9,126,955.89 | 10,639,420.77 | 10,251,016.12 | 11,696,742.76 |
| 流动负债合计 | 88,786,844.92 | 93,520,988.5 | 229,658,890.11 | 233,316,832.88 |
| 非流动负债: | | | | |
| 递延收益 | 2,625,000 | 2,700,000 | 2,775,000 | 2,850,000 |
| 递延所得税负债 | 788,931.56 | 841,527 | 894,122.44 | 946,717.87 |
| 非流动负债合计 | 3,413,931.56 | 3,541,527 | 3,669,122.44 | 3,796,717.87 |
| 负债合计 | 92,200,776.48 | 97,062,515.5 | 233,328,012.55 | 237,113,550.75 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 274,400,000 | 274,400,000 | 274,400,000 | 274,400,000 |
| 资本公积 | 1,175,415,514.58 | 1,175,415,514.58 | 1,175,415,514.58 | 1,175,415,514.58 |
| 减:库存股 | 29,250,050.22 | 26,141,608.31 | 11,968,285.89 | 11,968,285.89 |
| 盈余公积 | 20,100,414.53 | 20,100,414.53 | 20,100,414.53 | 20,100,414.53 |
| 未分配利润 | -673,467,656.4 | -660,224,074.32 | -591,957,497.26 | -563,326,005.75 |
| 归属于母公司股东权益合计 | 767,198,222.49 | 783,550,246.48 | 865,990,145.96 | 894,621,637.47 |
| 少数股东权益 | -72,697,227.17 | -71,140,639.51 | -65,429,727.51 | -62,110,444.75 |
| 股东权益合计 | 694,500,995.32 | 712,409,606.97 | 800,560,418.45 | 832,511,192.72 |
| 负债和股东权益合计 | 786,701,771.8 | 809,472,122.47 | 1,033,888,431 | 1,069,624,743.47 |
| 公告日期 | 2026-04-30 | 2026-04-30 | 2025-10-31 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |